Latest "Boehringer Ingelheim Corporation" News Stories - Page: 2

05:08 EDT 20th March 2019 | BioPortfolio

Here are the most relevant search results for "Boehringer Ingelheim Corporation" found in our extensive news archives from over 250 global news sources.

More Information about Boehringer Ingelheim Corporation on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Boehringer Ingelheim Corporation for you to read. Along with our medical data and news we also list Boehringer Ingelheim Corporation Clinical Trials, which are updated daily. BioPortfolio also has a large database of Boehringer Ingelheim Corporation Companies for you to search.

Showing "Boehringer Ingelheim Corporation" News Articles 26–50 of 989

Extremely Relevant

Boehringer Ingelheim Expands Oncolytic Virus Program and Buys ViraTherapeutics for $245 Million

Heidelberg, Germany-based Boehringer Ingelheim has exercised its option to buy an EMBL Ventures portfolio company, ViraTherapeutics. This follows a collaboration and option deal inked between the two companies in August 2016.

New patent expiration for Boehringer Ingelheim drug STRIVERDI RESPIMAT

Annual Drug Patent Expirations for STRIVERDI+RESPIMAT Striverdi Respimat is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are eighteen… The post New patent expiration for Boehringer Ingelhe... The post New patent expiration for Boehringer Ingelheim drug STRIVERDI RESPIMAT appeared first on Biotechblog.

Following Sanofi Cuts Last Week, Boehringer Ingelheim to Cut 327 Jobs in France

More pharma workers in France are receiving coal in their stockings this year after Germany-based Boehringer Ingelheim announced plans to cut about 300 jobs in that country as part of a reorganization of its operations in France.

Boehringer Ingelheim axes biosimilars development outside US

Boehringer Ingelheim has said it has axed development of its biosimilars outside Europe, focusing instead on getting its Humira near-copy on the US market as soon as possible. BI got its biosimilar of AbbVie’s inflammatory diseases drug Humira (ad...

Boehringer Ingelheim Acquires All Shares of ViraTherapeutics to Develop Next Generation Viral-Based Immuno-Oncology Therapies

INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced that it has acquired all shares of ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic viral therapies. ViraTherapeutics developed the lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP)), which is being investigated alone and in combination...

Boehringer Ingelheim expands virtual clinical trials capabilities

Boehringer Ingelheim is scaling its virtual clinical trial capabilities through an agreement with the mobile technology company Science 37.

Boehringer Ingelheim and Epizyme Partner for Development of Novel Epigenetic Oncology Therapies

CAMBRIDGE, Mass. and INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim and Epizyme, Inc. (Nasdaq: EPZM) today announced a new global collaboration focused on the research, development and commercialization of novel small molecule inhibitors directed toward two previously unaddressed epigenetic targets as potential therapies for people with cancer. Specifically, these targets are ...

Boehringer Ingelheim opens new global R&D centre for veterinary vaccine in France

Boehringer Ingelheim has inaugurated its new global centre for biological research and development at its Lyon Porte─des─Alpes (LPA) location in Saint─Priest France, in the presence of Delphine Gény─Stephann, Secretary of State

Martin Heidecker of Boehringer Ingelheim Venture Fund talks about their interest in science platform technologies and early stage investments

In this episode of PharmaTelevision News Review, Fintan Walton talks to Martin Heidecker, Director of Global Business Analysis at Boehringer Ingelheim

Boehringer Ingelheim Buys ViraTherapeutics

Boehringer Ingelheim has taken an option to buy all the shares of ViraTherapeutics, an Austrian biopharma that specializes in developing immunotherapy drugs based on oncolytic viruses. The total transaction value of €210 million is based on an option and share purchase agreement that the two companies signed in August 2016.

Boehringer Ingelheim acquires Pharmaxis’ anti-inflammatory candidate

Boehringer Ingelheim exercises option and acquires global ownership of Pharmaxis’ investigational anti-inflammatory drug candidate PXS4728A, including associated intellectual property rights. PXS4728A is a highly selective oral small molecule inhibitor of vascular adhesion protein-1 that has shown activity in pre-clinical investigation in non-alcoholic steatohepatitis (NASH). Drug candidate will...

Boehringer Ingelheim signs drug discovery pact with 3B Pharmaceuticals

3B Pharmaceuticals has announced a multi-year collaboration with Boehringer Ingelheim, for peptide-led drug discovery.

Boehringer Ingelheim Grows Strongly in the UK: Zinta Krumins, Managing Director

In this episode of PharmaTelevision News Review, Fintan Walton talks to Zinta Krumins, Managing Director of Boehringer Ingelheim UK and Ireland

Boehringer Ingelheim to market GST's stem cell veterinary product, Arti─Cell Forte in European Union

The Boehringer Ingelheim Animal Health Business Unit and Global Stem Cell Technology (GST) entered into a partnership to enable European veterinarians and horse owners to benefit from groundbreaking innovation.

Boehringer Ingelheim appoints new chief medical officer

Boehringer Ingelheim has announced the appointment of Dr Mehdi Shahid as chief medical officer.

Boehringer Ingelheim and IBM bring blockchain to clinical trials

Boehringer Ingelheim and IBM Canada are using blockchain technology for the first time in a clinical trial setting to test the technologyâs trial management capabilities.

Boehringer Ingelheim increases awareness of health with the micro enterprise project 'Elephants' in South India

Boehringer Ingelheim announced the start of a new self-help project in India to increase awareness of hygiene and health. On the occasion of the Global Handwashing Day 2018, October 15 the company would like to draw attention to the hygienic conditions in the impoverished regions around the world.

AGC to acquire Malgrat Pharma Chemicals from Boehringer Ingelheim

AGC, a world─leading manufacturer of glass, chemicals and high─tech materials, has entered into an agreement with Boehringer Ingelheim to acquire Malgrat Pharma Chemicals, S.L.U. (MPC). MPC is a subsidiary

Boehringer Ingelheim and Epizyme Ink Collaboration Deal With $15 Million up Front and $280 Millio...

Boehringer Ingelheim and Epizyme signed a global collaboration deal to identify, develop and market cancer therapies. The deal could exceed $300 million.

Xynomic Pharmaceuticals Picks Up Second Cancer Drug from Boehringer Ingelheim in $800 Million Deal

Xynomic Pharmaceuticals, a pharma company with roots in both the U.S. and China, forged a deal worth up to $800 million to acquire a Phase II ready cancer treatment from Germany-based Boehringer Ingelheim International GmbH.

Boehringer expands manufacturing facility in Shanghai

German firm Boehringer Ingelheim has expanded the capacity of its commercial manufacturing site for biologics in Shanghai, China. The expansion will see the installation of an additional bioreactor into the company’s OASIS Shanghai facility. “We are fully committed to our biopharmaceutical contract manufacturing business in China and it is our utmost goal to serve our customers and their patie...

Boehringer Ingelheim & Eli Lilly: Empagliflozin Meets Primary Efficacy Endpoint

INDIANAPOLIS (dpa-AFX) - Boehringer Ingelheim and Eli Lilly and Company (LLY) announced that empagliflozin met the primary efficacy endpoint, defined as a change from baseline in A1C versus placeb...

Boehringer Ingelheim and Epizyme Ink Collaboration Deal With $15 Million Upfront and $280 Million...

Boehringer Ingelheim and Epizyme signed a global collaboration deal to identify, develop and market cancer therapies. The deal could exceed $300 million.

Boehringer Ingelheim's NexGard & NexGard Spectra gets approval to treat cutaneous diseases demodicosis and sarcoptic mange in EU & Australia

Boehringer Ingelheim received approval to expand the label claims for its NexGard brands for the treatment of two severe skin diseases in dogs. Both NexGard and NexGard Spectra are now approved for the treatment

Why Boehringer Ingelheim is embracing 'Research Beyond Borders' to drive organic growth

At their Annual Press Conference on April 22, 2015 in the Boehringer Ingelheim Center Prof Dr Andreas Barner, Chairman of the Board explained to PharmaVentures' Dr Fintan Walton how the research-driven pharmaceutical company is now positioned for future growth. “After a challenging 2014, the focus for us now is on launching numerous additional new products and on our profitability,” said Profe...

Quick Search


News Quicklinks